Sana Biotechnology (NASDAQ:SANA) Raised to Hold at Wall Street Zen

Sana Biotechnology (NASDAQ:SANA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Other equities research analysts have also recently issued reports about the stock. Wedbush upped their target price on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday. HC Wainwright dropped their price target on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday. JMP Securities set a $8.00 price objective on Sana Biotechnology in a research note on Thursday, October 30th. Citizens Jmp lifted their target price on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Sana Biotechnology Price Performance

Shares of SANA stock traded up $0.04 during trading hours on Friday, hitting $4.09. The stock had a trading volume of 5,461,342 shares, compared to its average volume of 6,789,225. The firm has a market capitalization of $972.63 million, a PE ratio of -4.22 and a beta of 1.94. The stock’s 50 day moving average is $4.06 and its 200 day moving average is $3.34. Sana Biotechnology has a twelve month low of $1.26 and a twelve month high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. As a group, equities analysts predict that Sana Biotechnology will post -1.16 earnings per share for the current year.

Institutional Investors Weigh In On Sana Biotechnology

Several institutional investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Sana Biotechnology by 4.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company’s stock valued at $188,000 after purchasing an additional 2,023 shares in the last quarter. Savant Capital LLC increased its holdings in Sana Biotechnology by 5.6% in the third quarter. Savant Capital LLC now owns 66,414 shares of the company’s stock valued at $236,000 after buying an additional 3,500 shares in the last quarter. Viewpoint Capital Management LLC lifted its position in shares of Sana Biotechnology by 19.1% during the 2nd quarter. Viewpoint Capital Management LLC now owns 28,045 shares of the company’s stock valued at $77,000 after acquiring an additional 4,500 shares during the period. Captrust Financial Advisors boosted its stake in shares of Sana Biotechnology by 43.8% during the 2nd quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock worth $43,000 after acquiring an additional 4,807 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Sana Biotechnology by 46.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock worth $42,000 after acquiring an additional 4,931 shares during the period. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.